Single drug regimen for carcinoma esophagus which shows significant decrease in tumor size in 15 – 20% of patients incorporates which drug?
**Core Concept**
The question is testing knowledge of a specific chemotherapeutic agent used in the treatment of esophageal carcinoma. The correct answer is a drug that has shown significant antitumor activity in this malignancy.
**Why the Correct Answer is Right**
The correct answer is a platinum-based chemotherapeutic agent called Cisplatin. Cisplatin works by inducing cross-linking of DNA, thereby inhibiting DNA synthesis and triggering apoptosis in cancer cells. The drug is often used in combination with other agents such as 5-fluorouracil (5-FU) and radiotherapy for the treatment of esophageal carcinoma.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it does not match the description of the drug regimen mentioned in the question.
* **Option B:** This option is incorrect because it is not a commonly used chemotherapeutic agent for esophageal carcinoma.
* **Option C:** This option is incorrect because it is a targeted therapy used in the treatment of certain types of cancer, but it is not the correct answer based on the description provided.
**Clinical Pearl / High-Yield Fact**
Cisplatin is a key component of the chemotherapy regimen for esophageal carcinoma, and its use is associated with significant antitumor activity in a subset of patients.
**Correct Answer:** C. Cisplatin